SCHEMBL23601038

SCHEMBL23601038

CN(c1cccc(C#Cc2ccc(Cl)cc2)c1)c1nc2nncn2c2cc(Cl)ccc12

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
MAT2A P31153 6/20 0.34
GRM4 Q14833 1/20 0.34
PRMT5 O14744 2/20 0.33
GRM5 P41594 2/20 0.33
CYP1A2 P05177 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
EGFR P00533 2/20 0.32
CSF1R P07333 2/20 0.32
HRH4 Q9H3N8 1/20 0.32
CSNK2A2 P19784 1/20 0.32
CSNK2B P67870 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23601040 0.89 FNTA (0.34) FNTAFNTBMAT2APRMT5CYP1A2
SCHEMBL23601289 0.89 MAT2A (0.34) FNTAFNTBMAT2APRMT5CYP1A2
SCHEMBL23601039 0.88 PTGES (0.36) FNTAFNTBMAT2APRMT5CYP1A2
SCHEMBL23601286 0.88 FNTA (0.36) FNTAFNTBMAT2APRMT5CYP1A2
SCHEMBL23601818 0.86 HTT (0.33) FNTAFNTBMAT2APRMT5CYP1A2
SCHEMBL23576987 0.86 FNTA (0.32) FNTAFNTBMAT2APRMT5CYP1A2
SCHEMBL23600780 0.86 EGFR (0.33) FNTAFNTBMAT2APRMT5CYP1A2
SCHEMBL23601201 0.85 GRM5 (0.36) GRM5SMN1; SMN2CSF1RCSNK2A2CSNK2B
SCHEMBL29909225 0.85 PTGES (0.39) MAT2APRMT5GRM5CYP1A2HRH4
SCHEMBL29909831 0.85 MAT2A (0.33) FNTAFNTBMAT2AHRH4CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK FNTA 968/4885FNTB 743/4885MAT2A 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.